Bioextrax AB (DE:85X0)

FRANKFURT:85X0

85X0

Bioextrax AB

RESEARCH TOOLSreports

Bioextrax AB (85X0) Price & Analysis

0 Followers

85X0 Stock Chart & Stats

€0.17

-€0.03(-9.58%)

At close: Jan 08 4:00 PM EST

€0.17

-€0.03(-9.58%)

Day’s Range― - ―

52-Week Range€0.15 - €0.34

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€11.16M

Enterprise Value€101.16M

Total Cash (Recent Filing)€3.93M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.97

Next Earnings

May 14, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding46,306,927

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.47

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)€500.08K

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero reported debt materially reduces refinancing and interest-rate risk over the medium term, giving management optionality to pursue R&D, scale pilot plants, or secure partnership terms without immediate debt service. This structural flexibility supports long-term strategy execution.

Diversified Commercial ModelA business model combining product sales, licensing of process technology, and contract R&D creates multiple durable revenue pathways. This mix lets the company monetize IP, capture partner-funded development, and reduce reliance on a single revenue source as it scales industrial biotech offerings.

Evidence Of Operating LeverageThe 2023 positive gross margin indicates the underlying processes can achieve margin improvement when volumes or yields rise. If the company can grow higher-margin product sales or license more processes, that operating leverage could translate into sustainable margin recovery over the next several quarters.

Bears Say

Structural UnprofitabilityPersistent negative gross profit and deep operating losses signal the core activities are not currently economically self-sustaining. Over a multi-month horizon this undermines reinvestment capacity and means profitability depends on material revenue scale-up or cost restructuring to become durable.

Consistent Negative Cash FlowRepeated negative operating and free cash flows, with accelerating burn in 2025, indicate the business is not self-funding. This structural cash deficit increases the probability of future external financing needs, which can dilute shareholders or constrain investment in commercialization.

Eroding Equity BaseDeclining equity across multiple years reflects cumulative losses and reduces the balance-sheet buffer against shocks. A shrinking capital base limits capacity to absorb further losses or to fund scale-up internally, raising reliance on partner funding or capital raises for durable growth.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

2M ago

85X0 FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was €0.15 and its highest was €0.34 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is €11.16M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is May 14, 2026 which is in 34 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Feb 19, 2026. The company reported -€0.01 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.01.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is >-0.01.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 46,306,927 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -€0.01 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went up 2.92%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in DE:85X0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. It harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids from bacteria. The company was incorporated in 2014 and is based in Lund, Sweden.